Mabion extends agreement with Croatian CRO for Mabthera biosimilar study

The pace of recruitment is the biggest challenge in carrying out trials in Eastern Europe, says Mabion which has extended an agreement with local CRO Altiora for its biosimilar study.

Polish biopharma firm Mabion’s lead candidate is a biosimilar of Roche’s MabThera (rituximab) - a monoclonal antibody intended to treat lymphoma, leukemia and rheumatoid arthritis – known as MabionCD20.
Last week the firm obtained the consent of regulators in Croatia, Bosnia and Herzegovina, Serbia and Poland to perform clinical trials of the drug in patients with diffuse large B-cell lymphoma, and announced it would extend a service agreement with Zagreb, Croatia-based contract research organisation (CRO) Altiora to carry out the work.
“Altiora presented the most advantageous offer including comprehensive management of project,” Mabion’s CEO Maciej Wieczorek told Outsourcing-Pharma.com. “Based on previous cooperation, we have developed a clear trail of communication and procedures, and therefore we have entrusted execution of this task to proven partner.”
Furthermore, Altiora’s rapid pace of recruitment was a decisive factor in selecting the CRO, Wieczorek told us, adding patient recruitment is the biggest challenge in carrying out trials in the Central and Eastern Europe (CEE) region.
“[This is] because the sponsor of the study has no effect on the rate of patients for inclusion in the study. It is difficult to predict in advance the number of patients enrolled in the study by doctors who meet the inclusion criteria.”

The lymphoma study will involve approximately 140 patients and Mabion said it is close to receiving approval to conduct trials in Bulgaria, Romania, Moldova, Ukraine, Georgia and Hungary, which would also be carried out by Altiora.
If successful, Mabion intends to register MabionCD20 in all the global markets where Mabthera is sold. According to Roche’s annual report , sales of the monoclonal antibody in 2013 clocked in at 6.9bn Swiss Francs ($7.2bn). The US patent is set to expire in April 2015 .

此博客中的热门博文

What is preclinical testing?

In the process of preclinical testing of a compound or biological agent into a drug, the compound involved must go through the testing phase. First, we need to identify potential targets that can treat the disease. Then, a variety of compounds or preparations are screened out. Any compound that has shown potential as a drug for the treatment of this disease needs to be tested for toxicity before clinical testing to reduce the possibility of injury. preclinical testing What is the basis of preclinical testing? According to US Food and Drug Administration (FDA) regulations, a series of tests are required before a new drug is approved for use. In the first stage, basic research determines a hypothetical target for the treatment of a certain disease, and then screens small molecules or biological compounds to discover any substance with the potential to treat the disease. Then, a preclinical research phase followed, before which, as described above, the potential toxicity of the compou

阅读全文

Inventory of the three major in vitro pharmacokinetic research methods

The metabolic properties of a compound are an essential factor in whether or not it can be used as a drug in the clinical setting, so pharmacokinetic studies of newly synthesized compounds are required in drug development. In vitro incubation with liver microsomes, recombinant CYP450 enzyme lines, and in vitro incubation with hepatocytes are some of the more common in vitro drug metabolism methods. 1. In vitro incubation method with liver microsomes The metabolic stability and metabolic phenotypes of candidate compounds in different species of liver microsomes are good predictors of the metabolic properties of compounds in vivo. They are practical tools for evaluating candidate compounds in the pre-development phase of drug development. Liver microsomes include rat liver microsomes, human liver microsomes, canine liver microsomes, monkey liver microsomes, and mouse liver microsomes. In in vitro incubation of the liver, microsomes are the "gold standard" for in vitro d

阅读全文

Novel Parkinson’s Therapies Possible with New Mouse Model

Parkinson's disease (PD) is a neurodegenerative disorder that is marked by the accumulation of the protein, α-synuclein (αS), into clumps known as Lewy bodies, which diminish neural health. Now, researchers from Brigham and Women's Hospital (BWH) report the development of a mouse model to induce PD-like αS aggregation, leading to resting tremor and abnormal movement control. The mouse responds to L-DOPA, similarly to patients with PD. The team's study (“Abrogating Native α-Synuclein Tetramers in Mice Causes a L-DOPA-Responsive Motor Syndrome Closely Resembling Parkinson’s Disease”) on the use of this transgenic mouse model appears in Neuron . “α-Synuclein (αS) regulates vesicle exocytosis but forms insoluble deposits in PD. Developing disease-modifying therapies requires animal models that reproduce cardinal features of PD. We recently described a previously unrecognized physiological form of αS, α-helical tetramers, and showed that familial PD-causing missense mutati

阅读全文

Shanghai Medicilon Inc.

搜索此博客